Published in J Med Chem on July 14, 2005
Why did NMDA receptor antagonists fail clinical trials for stroke and traumatic brain injury? Lancet Neurol (2002) 3.30
Sedative and anticonvulsant drugs suppress postnatal neurogenesis. Ann Neurol (2008) 2.46
Anthranilic acid amides: a novel class of antiangiogenic VEGF receptor kinase inhibitors. J Med Chem (2002) 1.62
Statistical inference for stochastic simulation models--theory and application. Ecol Lett (2011) 1.60
Expression of glutamate receptor subunits in human cancers. Histochem Cell Biol (2009) 1.31
NMDA antagonist inhibits the extracellular signal-regulated kinase pathway and suppresses cancer growth. Proc Natl Acad Sci U S A (2005) 1.30
Intronic RNAs constitute the major fraction of the non-coding RNA in mammalian cells. BMC Genomics (2012) 1.26
Glutamate receptor expression in multiple sclerosis lesions. Brain Pathol (2007) 1.26
How individual species structure diversity in tropical forests. Proc Natl Acad Sci U S A (2007) 1.17
Recruitment in tropical tree species: revealing complex spatial patterns. Am Nat (2009) 1.06
Late-onset motoneuron disease caused by a functionally modified AMPA receptor subunit. Proc Natl Acad Sci U S A (2005) 1.06
Functional characterization and comparison of the outer blood-retina barrier and the blood-brain barrier. Invest Ophthalmol Vis Sci (2005) 1.06
Antiepileptic drugs and brain development. Epilepsy Res (2009) 1.04
Multiple sclerosis and glutamate. Ann N Y Acad Sci (2003) 1.03
Glutamate AMPA receptors change in motor neurons of SOD1G93A transgenic mice and their inhibition by a noncompetitive antagonist ameliorates the progression of amytrophic lateral sclerosis-like disease. J Neurosci Res (2006) 1.03
Testing the independent species' arrangement assertion made by theories of stochastic geometry of biodiversity. Proc Biol Sci (2012) 1.01
Glutamate antagonists limit tumor growth. Biochem Pharmacol (2002) 0.95
Ecological-economic modeling for biodiversity management: potential, pitfalls, and prospects. Conserv Biol (2006) 0.93
Fluoxetine inhibits the extracellular signal regulated kinase pathway and suppresses growth of cancer cells. Cancer Biol Ther (2008) 0.90
Mechanism-based inhibition: deriving K(I) and k(inact) directly from time-dependent IC(50) values. J Biomol Screen (2009) 0.89
Allosteric MEK1/2 inhibitor refametinib (BAY 86-9766) in combination with sorafenib exhibits antitumor activity in preclinical murine and rat models of hepatocellular carcinoma. Neoplasia (2013) 0.86
On the importance of small changes in RNA expression. Methods (2013) 0.85
Glutamate receptors in laryngeal cancer cells. Anticancer Res (2011) 0.84
Mechanisms of disease: motoneuron disease aggravated by transgenic expression of a functionally modified AMPA receptor subunit. Ann N Y Acad Sci (2005) 0.84
AMPA antagonists inhibit the extracellular signal regulated kinase pathway and suppress lung cancer growth. Cancer Biol Ther (2007) 0.83
Some cannabinoid receptor ligands and their distomers are direct-acting openers of SUR1 K(ATP) channels. Am J Physiol Endocrinol Metab (2011) 0.81
On the challenge of fitting tree size distributions in ecology. PLoS One (2013) 0.81
Extended therapeutic time window after focal cerebral ischemia by non-competitive inhibition of AMPA receptors. Brain Res (2006) 0.79
Neighborhood diversity of large trees shows independent species patterns in a mixed dipterocarp forest in Sri Lanka. Ecology (2015) 0.78
Phosphonate quinoxalinedione AMPA antagonists. Restor Neurol Neurosci (2000) 0.77
Antiviral activity of Engystol® and Gripp-Heel®: an in-vitro assessment. J Immune Based Ther Vaccines (2010) 0.76
Effect of Neurexan on the pattern of EEG frequencies in rats. BMC Complement Altern Med (2012) 0.75
Tolerance to and Dependence on Alprazolam are Due to Changes in GABAa Receptor Function and Are Independent of Exposure to Experimental Set-up. Restor Neurol Neurosci (1998) 0.75
Optimization of allosteric MEK inhibitors. Part 1: Venturing into underexplored SAR territories. Bioorg Med Chem Lett (2013) 0.75